Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Cardiology/Vascular Diseases | Hematology

Clinical Trials: Venous Thrombosis


A listing of clinical trials currently looking for volunteers to enroll in Venous Thrombosis studies. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Birmingham : University of Alabama at Birmingham

Clarification of Optimal Anticoagulation Through Genetics

Dothan :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Arizona

Glendale : Arrowhead Hospital/Phoenix Heart, PLLC

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Arkansas

Little Rock : Arkansas Children's Hospital Research Institute

Treatment of Blood Clots in Children With Cancer

California

Los Angeles :

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Orange : St. Joseph Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Palo Alto : Stanford University Medical Center

Treatment of Blood Clots in Children With Cancer

San Francisco : University of California San Francisco

Clarification of Optimal Anticoagulation Through Genetics

Stanford : Stanford University Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Connecticut

Danbury : Danbury Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Norwich : Eastern Connecticut Hematology and Oncology Associates

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Delaware

Newark : Christiana Care Health Systems

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

District of Columbia

Washington : Georgetown University Lombardi Cancer Center

Treatment of Blood Clots in Children With Cancer

Florida

Clearwater :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Ft. Myers :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Gainesville : University of Florida

Clarification of Optimal Anticoagulation Through Genetics

Jacksonville : Nemours Children's Clinic/Jacksonville

Treatment of Blood Clots in Children With Cancer

Orlando : Florida Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

View More »

Tampa : Pepin Heart Hospital / University Community Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Tampa : St. Joseph's Children's Hospital of TampaPediatric Hematology/Oncology Research Department

Treatment of Blood Clots in Children With Cancer

Georgia

Atlanta : Emory University

Treatment of Blood Clots in Children With Cancer

Augusta : Georgia Health Sciences University

Clarification of Optimal Anticoagulation Through Genetics

Jonesboro :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Illinois

Chicago : University of Illinois at Chicago

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Chicago : Rush University Medical Center

Treatment of Blood Clots in Children With Cancer

Hinsdale : Adventist Midwest Health

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Springfield : Prairie Education and Research Cooperative

A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis

Springfield : Southern Illinois University

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

View More »

Winfield : Central DuPage Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Indiana

Indianapolis : CorVasc

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Lafayette :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Iowa

Iowa City : University of Iowa Carver's College of Medicine

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Kentucky

Florence : St. Elizabeth Healthcare of Northern Kentucky

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Louisvile : Kosair Charities Pediatric Clinical Research Unit- University of Louisville

Treatment of Blood Clots in Children With Cancer

Louisiana

Covington :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

New Orleans : Tulane University Health Science Center

Clarification of Optimal Anticoagulation Through Genetics

Maine

Portland : Maine Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Maryland

Baltimore : Johns Hopkins Bayview Medical Center

A Pilot Study Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients

Baltimore : University of Maryland School of Medicine

Clarification of Optimal Anticoagulation Through Genetics

Massachusetts

Boston : Massachusetts General Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Michigan

Ann Arbor : Ann Arbor Veteran's Administration Health System

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Ann Arbor : University of Michigan Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Detroit : Henry Ford Health System

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Detroit : Henry Ford Hospital

Clarification of Optimal Anticoagulation Through Genetics

Minnesota

Rochester : Mayo Clinic

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Rochester : Mayo Clinic College of Medicine

Clarification of Optimal Anticoagulation Through Genetics

Missouri

St. Louis : Washington University School of Medicine

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

St. Louis : Washington University School of Medicine

Clarification of Optimal Anticoagulation Through Genetics

Montana

Butte :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Nebraska

Lincoln : Saint Elizabeth Regional Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

New Jersey

Teaneck : Holy Name Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

New Mexico

Albuquerque : University of New Mexico

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Albuquerque : University of New Mexico

Treatment of Blood Clots in Children With Cancer

New York

Bronx : Montefiore Medical Center

Clarification of Optimal Anticoagulation Through Genetics

New York : Cornell Weill Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

New York : Mount Sinai School of Medicine

Clarification of Optimal Anticoagulation Through Genetics

Staten Island : Staten Island University Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

North Carolina

Chapel Hill : University of North Carolina at Chapel Hill

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Durham : Duke University

Clarification of Optimal Anticoagulation Through Genetics

Durham : Duke Children's Hospital

Treatment of Blood Clots in Children With Cancer

Winston Salem : Wake Forest University Baptist Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Winston-Salem : Forsyth Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Ohio

Cincinatti : Good Samaritan Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Cleveland : Cleveland Clinic

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Colombus : Univeristy Medical Center

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Columbus : Riverside Methodist Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Toledo : Jobst Vascular Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Oregon

Portland : Oregon Health & Science University

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Portland : Oregon Health and Science University

Treatment of Blood Clots in Children With Cancer

Pennsylvania

West Reading : The Reading Hospital and Medical Center Clinical Trials Office

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

View More »

Bethlehem : St. Luke's Hospital and Health Network

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Camp Hill :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Ephrata :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Philadelphia : Albert Einstein Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Philadelphia : Temple University Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Philadelphia : Hospital of the University of Pennsylvania

Clarification of Optimal Anticoagulation Through Genetics

Pittsburgh : Allegheny General Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Pittsburgh : University of Pittsburgh Medical Center Presbyterian Shadyside

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Pittsburgh : The Western Pennsylvania Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Sellersville :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

West Reading : The Reading Hospital and Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Rhode Island

Providence : Rhode Island Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

South Carolina

Charleston : Medical University of South Carolina

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Charleston : Medical Center of South Carolina

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Tennessee

Memphis : St. Jude Children's Research Hospital

Treatment of Blood Clots in Children With Cancer

Nashville : Vanderbilt University

Clarification of Optimal Anticoagulation Through Genetics

Texas

Forth Worth : Cook Children's Medical Center

Treatment of Blood Clots in Children With Cancer

Galveston : University of Texas Medical Branch

Clarification of Optimal Anticoagulation Through Genetics

Utah

Murray : Intermountain Medical Center

Clarification of Optimal Anticoagulation Through Genetics

Salt Lake City : University of Utah

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Salt Lake City : University of Utah Health Care

Clarification of Optimal Anticoagulation Through Genetics

Virginia

Charlottesville : University of Virginia Health System

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Fredericksburg :

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Washington

Tacoma : MultiCare Health System

A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).

Wisconsin

Marshfield : Marshfield Clinical Research Foundation

Clarification of Optimal Anticoagulation Through Genetics

Milwaukee : Medical College of Wisconsin/Froedtert Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Australia

Melbourne : Royal Melbourne hospital

The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Parkville :

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Austria

Graz : 1160.86.43001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Wien :

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Wien : 1160.89.43001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Wien : 1160.86.43003 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Belgium

Brussel : 1160.89.32003 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Ghent : Drug Research Unit Ghent

A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.

Canada

Charlottetown : 1160.86.01003 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Edmonton :

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Edmonton : 1160.89.00002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Hamilton :

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Hamilton : St. Joseph's Healthcare Hamilton

The Risk of Venous Clotting in Patients After Renal Transplant

View More »

Hamilton : St Joseph's Healthcare Hamilton

Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

Montréal : Maisonneuve Rosemont Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Ottawa : 1160.89.00001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Ottawa : Ottawa Hospital, Parkdale Clinic

Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

Red Deer : 1160.86.01001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Toronto : St. Michael's Hospital

Atorvastatin for the Treatment of Retinal Vein Occlusion

Toronto : 1160.89.00005 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Vancouver : Diamond Health Care Centre

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Czech Republic

Brno : 1160.86.42001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Olomouc : 1160.86.42003 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Prague : 1160.86.42004 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Prague 5 : 1160.86.42002 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Denmark

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Finland

Jyväskylä : 1160.86.35801 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

France

Dijon : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Grenoble : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Marseille : 1160.89.33002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Montelimar : Cabinet

Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome

View More »

Paris : 1160.89.33001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Germany

Baesweiler : Chriurgische Praxisklinik

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Berlin : DEutsches Rotes Kreuz Schwesternschaft Berlin Gemeinnütziges Krankenhaus GmbH

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Bonn : Universitäts-Hautklinik Bonn

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Dresden : Universitätsklinikum Dresden

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Freiburg : Hautarztpraxis

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

View More »

Karlsbach : Akademie für Gefäßkrankheiten e.V.

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Mühldorf am Inn : Kardiologie Mühldorf am Inn

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

München : Gemeinschaftspraxis Mietaschk, Bilderling, Kaiser, Tato

Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Israel

Tel Hashomer :

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Italy

Bologna : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Genova :

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Milan : IRCCS H San Raffaele

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Roma : 1160.89.39001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Japan

Aomori :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Bunkyo-ku :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Chuoku :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Fukuoka :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Itabashi-ku :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

View More »

Kahoku-gun :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Kanazawa :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Kumamoto :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Maebashi :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Niigata :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Osaka :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Osakasayama :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Sakura :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Sapporo :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Sasebo :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Shinjuku-ku :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Shizuoka :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Tokushima :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Toyoake :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Tsu :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Wakayama :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Yokohama :

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Latvia

Riga : 1160.89.37101 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Lithuania

Vilnius : 1160.89.37001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Netherlands

Nijmegen : 1160.89.31003 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Utrecht : 1160.89.31004 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Norway

Bergen : 1160.89.47001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Spain

Alicante : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Madrid : 1160.89.34002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Madrid : 1160.89.34001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Soria : General Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Sweden

Hässleholm : 1160.86.46002 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Mölndal : 1160.86.46001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Stockholm : Karolinska University Hospital

Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture

Switzerland

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Zürich : 1160.89.41001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Thailand

Bangkok : 1160.89.66001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Tunisia

Tunis : Hospital Charle Nicolle

Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin

Ukraine

Dnipropetrovsk : 1160.89.38001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Lugansk : 1160.89.38002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Vinnytsya : 1160.89.38003 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age